MedTrace Logo

Cell-free Fetal DNA Circulating in the Maternal Plasma as a Marker for Morbidly Adherent Placenta

NCT02784886 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 63

Last updated 2016-05-27

No results posted yet for this study

Summary

The purpose of this study is to determine whether, in a high risk population (placenta praevia and previous caesarean or prenatal suspicion of morbidly adherent placenta (MAP)), the concentration of cell-free fetal DNA circulating in the maternal plasma is significantly increased in the subgroup of morbidly adherent placenta (MAP) cases , in order to determine if the dosage of cell-free fetal DNA circulating in the maternal plasma may be a useful biological tool to detect MAP, alone or in addition to the imagery findings (ultrasonography and RMI).

Conditions

  • Morbidly Adherent Placenta
  • Placenta Accreta
  • Placenta Increta
  • Placenta Percreta

Interventions

BIOLOGICAL

Women at high risk of MAP

Blood sample

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • Assistance Publique - Hôpitaux de Paris

    collaborator OTHER

  • University Hospital, Angers

    lead OTHER_GOV

Principal Investigators

  • Catherine Deneux-Tharaux, MD, PhD · Inserm U1153, Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Paris, France

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2015-11-30
Completion
2016-11-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02784886 on ClinicalTrials.gov